NeurologyLive® Friday 5 — August 29, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: A Global Calling for Universal Levodopa Access in Parkinson Disease Treatment: Michael S. Okun, MD

The director of the Norman Fixel Institute for Neurological Diseases at UF Health highlighted the need for equitable, worldwide access to levodopa for patients with Parkinson disease. [WATCH TIME: 6 minutes]

2:Analyzing Zorevunersen in Phase 3 Registrational Study for Dravet Syndrome: The EMPEROR Trial

Spanning across the United Kingdom, the United States, European Union, and Japan, the global phase 3 EMPEROR study of zorevunersen is expected to have data readout by the end of 2027.

3: Clinical Experience and Considerations With ALS Medication Tofersen: Sandeep Rana, MD

The neurophysiologist at Allegheny Health Network shared his clinical experience with tofersen in patients with SOD-1 ALS, while emphasizing the critical role of accessible genetic testing for patient identification. [WATCH TIME: 3 minutes]

4: NeuroVoices: Patricia Pozo-Rosich, MD, PhD, on Fremanezumab's Expanded Indication in Pediatrics

The head of the neurology department at Vall d’Hebron University Hospital provided clinical thoughts on fremanezumab’s expanded approval in pediatric migraine, the phase 3 SPACE study, and where future treatment may hold.

5: Elevating Patient Perspectives in the Mangement of Parkinson Disease: Esther Labib-Kiyarash, MSHA, CPHQ

At the 2025 ATMRD Congress, a patient advocate living with Parkinson disease emphasized the importance of amplifying patient voices at educational conferences for movement disorders. [WATCH TIME: 5 minutes]